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Chronic non-bacterial osteomyelitis (CNO) is an inflam-
matory, non-infectious disorder of the skeletal system
with unknown aetiology. Therapeutic options are
NSAIDs, steroids and DMARDs (MTX or sulfasalazine).
However, a considerable number of patients have a
severe disease course and bisphosphonates or TNF-a
blockade might be a therapeutic option.
We performed a multicentre, retrospective chart review
of all patients diagnosed with CNO in two paediatric
rheumatology centres in the last 10 years and treated
with pamidronate and/or TNF-a blockade. 17 patients
were treated with pamidronate and/or TNF-a blockade.
Out of these 17 patients, 10 were treated with pamidro-
nate alone and showed clinical improvement. Three of
the 17 patients were initially treated with TNF-a block-
ade; two had a positive response, one patient stopped
therapy due to minor side effects. Two or one patients
were initially treated with pamidonate or TNF-a block-
ade, respectively, but did not show clinical improvement.
Interestingly, switching from pamidronate to TNF-a
blockade or vice versa was associated with clinical
improvement in these patients. One patient was treated
with a combination therapy using pamidronate and TNF-
a blockade and showed a good clinical response.
Pamidronate and TNF-a blockade showed a good
response in therapy refractory CNO patients. Severe
adverse effects were not observed. However, some
patients seem to benefit from one of the two therapeutic
options in particular. Future studies are needed aiming to
identify clinical and/or radiological parameters that
might guide the decision to the appropriate treatment in
an individual patient.
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